Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy

Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67.

1984 • 4,180 citations

Immunosuppressive Strategies that are Mediated by Tumor Cells

2006 • 1,662 citations

Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell–suppressive activity

2008 • 1,185 citations

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

2006 • 1,180 citations

Interleukin‐10‐secreting type 1 regulatory T cells in rodents and humans

2006 • 1,156 citations

Gemcitabine Selectively Eliminates Splenic Gr-1+/CD11b+ Myeloid Suppressor Cells in Tumor-Bearing Animals and Enhances Antitumor Immune Activity

2005 • 1,010 citations

Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide

2005 • 878 citations

CD4⁺CD25⁺ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative

2004 • 854 citations

Regulatory T cells in cancer

2006 • 717 citations

Immunotherapy and chemotherapy — a practical partnership

2005 • 639 citations

Human Effector and Memory CD8+ T Cell Responses to Smallpox and Yellow Fever Vaccines

2008 • 594 citations

The anticancer immune response: indispensable for therapeutic success?

2008 • 556 citations

Transforming Growth Factor-β Production and Myeloid Cells Are an Effector Mechanism through Which CD1d-restricted T Cells Block Cytotoxic T Lymphocyte–mediated Tumor Immunosurveillance

2003 • 539 citations

CD4+CD25+ T Regulatory Cells Dependent on ICOS Promote Regulation of Effector Cells in the Prediabetic Lesion

2004 • 443 citations

Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response

2005 • 403 citations

Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors.

2003 • 401 citations

OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection

2008 • 383 citations

CCR6 expression defines regulatory effector/memory-like cells within the CD25+CD4+ T-cell subset

2004 • 314 citations

Cutting Edge: Expression of TNFR2 Defines a Maximally Suppressive Subset of Mouse CD4+CD25+FoxP3+ T Regulatory Cells: Applicability to Tumor-Infiltrating T Regulatory Cells

2008 • 302 citations

Immunogenic cancer cell death: a key-lock paradigm

2008 • 294 citations

Expression of ICOS In Vivo Defines CD4+ Effector T Cells with High Inflammatory Potential and a Strong Bias for Secretion of Interleukin 10

2003 • 247 citations

Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy.

2002 • 235 citations

Development and function of CD25+CD4+ regulatory T cells

2004 • 220 citations

Natural Regulatory T Cells and De Novo-Induced Regulatory T Cells Contribute Independently to Tumor-Specific Tolerance

2007 • 213 citations

Chemoimmunotherapy of Tumors: Cyclophosphamide Synergizes with Exosome Based Vaccines

2006 • 188 citations

Leveraging the Activity of Tumor Vaccines with Cytotoxic Chemotherapy

2005 • 180 citations

Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses

2006 • 155 citations

Expression of ICOS on Human Melanoma-Infiltrating CD4+CD25highFoxp3+ T Regulatory Cells: Implications and Impact on Tumor-Mediated Immune Suppression

2008 • 153 citations

Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: a consequence of eliminating precursor L3T4+ suppressor T-cells.

1989 • 149 citations

Nitric oxide-producing CD11b+Ly-6G(Gr-1)+CD31(ER-MP12)+cells in the spleen of cyclophosphamide–treated mice: implications for T-cell responses in immunosuppressed mice

2000 • 139 citations

NKT Cells in Tumor Immunity: Opposing Subsets Define a New Immunoregulatory Axis

2008 • 131 citations

Tumor-Induced CD11b+Gr-1+ Myeloid Cells Suppress T Cell Sensitization in Tumor-Draining Lymph Nodes

2008 • 129 citations

CD4⁺CD25⁺regulatory T cells limit the risk of autoimmune disease arising from T cell receptor crossreactivity

2005 • 125 citations

T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors.

1999 • 124 citations

Immunogenic anti-cancer chemotherapy as an emerging concept

2008 • 100 citations

Establishment and characterization of five human malignant mesothelioma cell lines derived from pleural effusions

1991 • 99 citations

Cyclophosphamide Induces the Development of Early Myeloid Cells Suppressing Tumor Cell Growth by a Nitric Oxide-Dependent Mechanism

2001 • 94 citations

Inducible costimulator-dependent IL-10 production by regulatory T cells specific for self-antigen

2004 • 75 citations

Elimination of cycling CD4+ suppressor T cells with an anti-mitotic drug releases non-cycling CD8+ T cells to cause regression of an advanced lymphoma.

1990 • 71 citations

Intra-tumoural regulatory T cells: A potential new target in cancer immunotherapy

2006 • 69 citations

Targeting the Effector Site with IFN-αβ-Inducing TLR Ligands Reactivates Tumor-Resident CD8 T Cell Responses to Eradicate Established Solid Tumors

2008 • 61 citations

CD101 Surface Expression Discriminates Potency Among Murine FoxP3+ Regulatory T Cells

2007 • 57 citations

Infiltration of a Mesothelioma by IFN-γ-Producing Cells and Tumor Rejection after Depletion of Regulatory T Cells

2007 • 34 citations

CD4+ T Cells Are Able to Promote Tumor Growth through Inhibition of Tumor-Specific CD8+ T-Cell Responses in Tumor-Bearing Hosts

2005 • 33 citations

Regulatory T cells inhibit Fas ligand‐induced innate and adaptive tumour immunity

2007 • 28 citations

Ifosfamide in malignant mesothelioma: a phase II study

1999 • 18 citations

Compared benefit of approved and experimental immunosuppressive therapeutic approaches in multiple sclerosis

2007 • 18 citations

Current chemotherapeutic treatment of malignant pleural mesothelioma

2004 • 7 citations